-
The DSRU team is at DIA Europe 2018 in Basel!
10th April 2018
Come and see us in the exhibition hall at Booth 112 to find out about our post-authorisation safety studies (PASS), as well as: DSRU Consultancy ECHO – our PV initiative for mental health products Our European network studies …and our wide range of other studies. DSRU Director, Professor Saad Shakir, will be chairing and speaking in […]
>Continue reading -
Big Data for Pharmacovigilance – programme now available!
22nd March 2018
We will be holding the first conference on “Big Data for Pharmacovigilance” on 20-21st June. Join us to hear how Big Data is revolutionising Pharmacovigilance from a panel of international experts from medicines regulators, industry and academia. What are the opportunities and challenges presented by Big Data and what can Pharmacovigilance learn from use of Big […]
>Continue reading -
DSRU Consultancy: World class science at a not-for-profit price
9th March 2018
Saad Shakir writes: DSRU Consultancy provides consultancy and advice on matters related to Pharmacovigilance, Pharmacoepidemiology, Risk Management and Risk Minimisation. The DSRU consultants are a team of epidemiologists, physicians, biomedical scientists, IT and data management professionals, who provide the consultancy work individually or as a team. We advise all kinds of companies from the some […]
>Continue reading -
Measuring the impact of pharmacovigilance activities: drug withdrawals since 2012 PV legislation
24th January 2018
The results from our study on evidence used to support product withdrawals and other regulatory actions have just been published in BMJ Open. The study concerned 18 medicinal products that were withdrawn, revoked or suspended in the EU for safety reasons following the implementation of new pharmacovigilance legislation on 1 July 2012 until 31 December […]
>Continue reading -
Hear about the revisions to GVP Module V with the DSRU’s training day
29th November 2017The newly updated GVP Module V now includes clarification of the scope of RMPs in relation to important identified or potential risks and missing information. Join us to hear from speakers including members of the EMA team who wrote the revised GVP Module V and updated the RMP template, as well as QPPV and other pharma staff. […]
>Continue reading
Latest News
- Big Data for Pharmacovigilance – programme now available!
- Measuring the impact of pharmacovigilance activities: drug withdrawals since 2012 PV legislation
- Hear about the revisions to GVP Module V with the DSRU’s training day
- New for 2018! The first conference on Big Data for Pharmacovigilance
- DSRU Consultancy launched!